Direzione e uffici C.I.B.

Direzione CIB:
Prof. Claudio Schneider
Email: claudio.schneider@Lncib.it

Segreteria CIB:
Prof. Roberto Gambari
Email: roberto.gambari@unife.it

SEGRETERIA ORGANIZZATIVA:
Elisabetta Lambertini
Tel: 0532/974451
Fax: 0532/974484
E-mail: lmblbt@unife.it

AMMINISTRAZIONE:
Vanessa Florit
Area di Ricerca
Padriciano, 99 - 34012 Trieste
Tel: 040/398979
Fax: 040/398990
E-mail: cib@lncib.it

Posta certificata C.I.B.:
cib@poste-certificate.it

Login



Accolla Roberto Stampa
RESPONSABILE DELLA U. O.

Cognome e Nome
Accolla Roberto
Qualifica Professore Ordinario
Facoltà
Medicina e Chirurgia
Dipartimento
Scienze Cliniche e Biologiche (DSCB)
Settore Scientifico Disciplinare
MED/04
E-mail Questo indirizzo e-mail è protetto dallo spam bot. Abilita Javascript per vederlo.

PERSONALE STRUTTURATO

Cognome e Nome DE LERMA BARBARO Andrea
Qualifica
Ricercatore confermato
Dipartimento Scienze Cliniche e Biologiche
Ente di appartenenza Università dell’Insubria
Cognome e Nome
MORTARA Lorenzo
Qualifica
Ricercatore confermato
Dipartimento Scienze Cliniche e Biologiche
Ente di appartenenza Università dell’Insubria
Cognome e Nome
NOONAN Douglas
Qualifica
Professore Associato
Dipartimento Scienze Cliniche e Biologiche
Ente di appartenenza Università dell’Insubria
Cognome e Nome
TEDESCHI Alessandra
Qualifica Tecnico
Dipartimento Scienze Cliniche e Biologiche
Ente di appartenenza Università dell’Insubria
Cognome e Nome
TOSI Giovanna
Qualifica
Ricercatore confermato
Dipartimento Scienze Cliniche e Biologiche
Ente di appartenenza Università dell’Insubria
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza

PERSONALE NON STRUTTURATO

Cognome e Nome
Frangione Valeria
Qualifica dottoranda
Dipartimento
DSCB
Ente di appartenenza
Università dell’Insubria
Cognome e Nome
Orlandi Chiara
Qualifica dottoranda
Dipartimento
DSCB
Ente di appartenenza
Università dell’Insubria
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza
Cognome e Nome
Qualifica
Dipartimento
Ente di appartenenza

LINEE DI RICERCA

1. New immunogenetic approaches for innovative vaccines and immunotherapies against cancer. Our research is focussed on the genetic modification of tumor cells by introducing the MHC class II transactivator gene (CIITA), discovered in our laboratory, to render tumor cells MHC class II positive and in this way, potential antigen presenting cells for their own tumor antigens to CD4 T cells, the immune subpopulation that is absolutely required for triggering all the effector mechanism (CTL and B cells) against cancer
2. Interactions between retroviruses (HIV and HTLV) and infected cells. We have discovered that CIITA not only upregulates MHC class II gene expression, thus controlling the initial phase of adaptive immune response, but also inhibits directly HIV and Human oncogenic retrovirus HTLV replication in infected cells. Our interest is therefore focussed toward the construction of a suitable methodology to activate endogenous CIITA or to transfer CIITA by appropriate vectors into retrovirus infected cells. We hope in this way to block viral spreading in HIV-infected patients and to counteract the oncogenic transformation of cells infected by HTLV.
Targeting innate immunity in anti-angiogenic cancer therapy Within the tumor microenvironment, host components including endothelial andstromal cells, as well as immune infiltrates, represent key therapeutic targets. Clinical inhibition of tumor vascularization with specific agents significantly prolongs patient survival for diverse tumor types; however, the clinical benefit is as yet in terms of months. An indicator of the importance of innate immunity in controlling angiogenesis is our discovery that the endogenous angiogenesis inhibitor, angiostatin, has immune cells as a primary target and requires immune cell derived IL-12. We are investigating the action of angiostatin on immune cells, particularly regarding phenotype switching and mechanisms.

TECNOLOGIE IN POSSESSO DELL'U. O.

  • Eukaryotic cell culture and propagation, including hemopoietic cells and tumor cells
  • All major assays for studying cellular and humoral immune response
  • Immunization protocols
  • Hybridoma technology
  • Cytoflorometry, analysis and cell sorting
  • Biochemical purification and analysis of cell surface markers
  • Gene cloning, sequencing and analysis
  • Molecular analysis of transcription

STRUMENTAZIONE

Denominazione
Struttura ove la strumentazione è allocata
Responsabile della strumentazione
FACS Aria II cell sorter, BD
Laboratorio di Patologia Generale e Immunologia, DSCB
Prof. Accolla
EPICS XL Cytofluorometer, Coulter Instruments
Laboratorio di Patologia Generale e Immunologia, DSCB
Prof. Accolla
Cell Culture Lab (2 laminar flow hoods, 3 CO2 Incubators)
Laboratorio di Patologia Generale e Immunologia, DSCB
Prof. Accolla

PUBBLICAZIONI

Tosi, G., A. De Lerma Barbaro, A. D’Agostino, M.T. Valle, A.M. Megiovanni, F. Manca, A. Caputo, G. Barbanti Brodano, and R.S. Accolla. 2000. HIV-Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines. Eur. J. Immunol. . 30:19-28.

Accolla, R.S, De Lerma Barbaro A., Mazza S., Casoli C., De Maria A., and Tosi G., 2001. The MHC class II transactivator: prey and hunter in infectious diseases. Trends Immunol. 22: 560-563.

De Lerma Barbaro, A., Tosi, G., Frumento, G., Bruschi, E., D’Agostino, A., Valle, M-T., Manca , F., and Accolla R.S., 2002. Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation. Eur. J. Immunol. 32: 1309-1318

Meazza, R., Comes, A., Orengo, A.M., Ferrini, S., and Accolla, R.S. 2003. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells. Eur. J. Immunol. 33: 1183-1192 (I.F.: 5,240)

Noonan, D.M., Gringeri, A., Meazza, R., Rosso, O., Mazza, S., Muca-Peria M., Le Buanec, H., Accolla R.S., Albini, A., Ferrini S., 2003. Identification of immunodominant epitopes in inactivated Tat-vaccinated healthy and HIV-1-infected volunteers. J Acquir Immune Defic Syndr. 33: 47-55

Casoli, C., De Lerma Barbaro, A., Pilotti, E., Bertazzoni, U., Tosi, G., Accolla, R.S. 2004. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2. Blood, 2004, 103: 995-1001

De Lerma Barbaro, A., F.A. Procopio, L. Mortara, G. Tosi, and R.S. Accolla. 2005. The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells. Eur.J.Immunol., 35: 603-611

Mortara, L., P. Castellani, R. Meazza, G. Tosi, A. De Lerma Barbaro, F.A. Procopio, A. Comes, L. Zardi, S. Ferrini, R. S. Accolla. 2006. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory. Clin. Cancer Res. 12:3435-3443

Tosi, G., E. Pilotti, L. Mortara, A. De Lerma Barbaro, C. Casoli, R.S. Accolla. 2006. Inhibition of HumanT-cell leukemia virus type2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y. 2006. Proc. Natl. Acad .Sci. USA, 103: 12861-12866.

Mortara, L., E. Balza, F.Sassi, P. Castellani, B. Carnemolla, A. De Lerma Barbaro, S. Fossati, G. Tosi, R. S. Accolla and L. Borsi. 2007. Therapy-Induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan . Eur.J.Immunol., 12: 3381-3392

DOTTORATI DI RICERCA

Componente U.O. Dottorato di Ricerca Coordinatore Sede
Roberto Accolla
Medicina Sperimentale e Oncologia
Prof.Roberto Accolla
Uninsubria
Douglas Noonan
As above
As above
As above
Giovanna Tosi
As above
As above
As above
Andrea De Lerma Barbaro
As above
As above
As above
Lorenzo Mortara
As above
As above
As above

CONGRESSI C.I.B.

Congressi Partecipazione
CNB4

CNB5

CNB6

CNB7

CNB8

CNB9
CNB10